SCHEMBL946089

SCHEMBL946089

O=C1C=CC(=O)N1CCCCCCCCON1C(=O)CCC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 7/20 0.57
FAAH O00519 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
LMNA P02545 2/20 0.57
HPGD P15428 2/20 0.57
HSP90AA1 P07900 1/20 0.57
TLR9 Q9NR96 1/20 0.57
ALDH1A1 P00352 1/20 0.57
TP53 P04637 1/20 0.57
MAPT P10636 1/20 0.57
PKM P14618 1/20 0.57
XBP1 P17861 1/20 0.57
MAPK1 P28482 1/20 0.57
HTT P42858 1/20 0.57
RECQL P46063 1/20 0.57
RAB9A P51151 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
GPR35 Q9HC97 1/20 0.57
GPR55 Q9Y2T6 1/20 0.57
ALOX12 P18054 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594145 1.00 MGLL (0.57) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL841624 0.98 MGLL (0.55) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL28704923 0.93 MGLL (0.52) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL4882564 0.86 MGLL (0.53) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL29270039 0.80 MGLL (0.67) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL18522835 0.76 ALOX12 (0.41) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL818349 0.75 MGLL (1.00) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL13815841 0.75 MGLL (1.00) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL20351983 0.75 MGLL (1.00) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL258626 0.75 MGLL (1.00) MGLLFAAHSMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2261666-B1 METHOD FOR DETECTION OF PNEUMOCOCCUS OTSUKA PHARMA CO LTD (JP) 2015-12-02 EP claimed
US-8241857-B2 Method for detection of pneumococcus OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-14 US claimed
US-11125742-B2 Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit LSI MEDIENCE CORPORATION (JP) 2021-09-21 US disclosed
US-20190285576-A1 SEMICONDUCTOR SENSOR, METHOD FOR PRODUCING THE SAME, AND COMBINED SENSOR TORAY INDUSTRIES, INC. (JP) 2019-09-19 US disclosed
EP-3531131-A1 SEMICONDUCTOR SENSOR AND MANUFACTURING METHOD FOR SAME, AND COMPOUND SENSOR Toray Industries, Inc. (JP) 2019-08-28 EP disclosed
EP-2728354-B1 NON-SPECIFIC REACTION INHIBITOR, METHOD FOR INHIBITING NON-SPECIFIC REACTION, AND KIT LSI MEDIENCE CORP (JP) 2018-06-13 EP disclosed
EP-2261666-B1 METHOD FOR DETECTION OF PNEUMOCOCCUS OTSUKA PHARMA CO LTD (JP) 2015-12-02 EP disclosed
US-8921124-B2 Pyrazole-based cyanine dye WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-12-30 US disclosed
US-20140193842-A1 NON-SPECIFIC REACTION INHIBITOR, METHOD FOR INHIBITING NON-SPECIFIC REACTION, AND KIT MITSUBISHI CHEMICAL MEDIENCE CORPORATION (JP) 2014-07-10 US disclosed
EP-2728354-A1 NON-SPECIFIC REACTION INHIBITOR, AND METHOD AND KIT FOR INHIBITING NON-SPECIFIC REACTION Mitsubishi Chemical Medience Corporation (JP) 2014-05-07 EP disclosed
WO-2013088141-A1 POLYPEPTIDE COMPRISING THE SEQUENCE EGPWLEEEEEAYG LINKED TO AN IMMUNOGENIC CARRIER ASTRIMMUNE LIMITED (GB) 2013-06-20 WO disclosed
EP-2261666-A1 METHOD FOR DETECTION OF PNEUMOCOCCUS Otsuka Pharmaceutical Co., Ltd. (JP) 2010-12-15 EP disclosed
US-7700741-B2 High affinity anti-N1,N12-diacetylspermine monoclonal antibody TRANS GENIC INC. (JP) 2010-04-20 US disclosed
US-20100093006-A1 HIGH AFFINITY ANTI-N1,N12-DIACETYLSPERMINE MONOCLONAL ANTIBODY NAGASE YUSEI 2010-04-15 US disclosed
US-20090069546-A1 PYRAZOLE-BASED CYANINE DYE WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-03-12 US disclosed
EP-2006289-A1 PYRAZOLE-TYPE CYANINE DYE Wako Pure Chemical Industries, Ltd. (JP) 2008-12-24 EP disclosed
EP-1985311-A1 AGENT FOR TARGETING DRUG TO CEREBRAL NEURON Kagoshima University (JP) 2008-10-29 EP disclosed
US-20060166297-A1 High affinity anti-N¹,N¹²-diacetylspermine monoclonal antibody TRANS GENIC INC. (JP) 2006-07-27 US disclosed
US-5807942-A ADDITION POLYMERIZABLE MONOMER UNIT IS ATTACHED TO ENZYME, ANTIBODY, ETC. AND RESULTING COMPOUND IS POLYMERIZED THROUGH DOUBLE BOND WITH ANOTHER MODIFIED ENZYME OR ANTIBODY OR WITH A MONOMER SUCH AS METHACRYLAMIDE, USED IN IMMUNOASSAY NOF CORPORATION (JP) 1998-09-15 US disclosed
US-5790627-A Method and apparatus for observing a specimen using an X-ray microscope RESEARCH DEVELOPMENT CORP. (JP) 1998-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069546-A1 PYRAZOLE-BASED CYANINE DYE CBR3, CYB5R3, TST MGLL 4698/4885FAAH 4141/4885SMN1; SMN2 4165/4885
US-11125742-B2 Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit KIT, SPR, SHBG MGLL 2928/4885FAAH 1624/4885SMN1; SMN2 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.